Volume 4, Issue 4 (Autumn 2018)                   Caspian.J.Neurol.Sci 2018, 4(4): 178-183 | Back to browse issues page

XML Print

1- Department of Neurology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran , kavianghandehari@yahoo.com
2- School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3- Department of Neurology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract:   (1534 Views)
Despite the development of Intravenous thrombolysis with tissue Plasminogen Activator (IVtPA) guidelines in each affiliated stroke center, protocol violations may be observed in each hospital with IVtPA facilities. An extensive search of scientific electronic databases including PubMed, OVID, Index Medicus, Index Copernicus, Google, ISI, and Scopus was performed with keywords of Thrombolysis, Off-label, Out of Protocol, Violation, Time Window, Dose, tPA, and Stroke terminated on 01 May 2018. Safety and functional outcomes are less favorable beyond three hours; however, the wider time window until 4.5 hours is recommended. Lower dose of alteplase (0.6 mg/kg) is approved in Japan. The proposed dose of tPA in Iranian population is similar to that of the Japanese. Overall, the outcomes in patients treated with off-label IVtPA or protocol violation were better than those of the controls based on registry data. There is little disagreement about time window of IVtPA. The dose of 0.6 mg/kg is used in some Asian countries with similar therapeutic results.
Full-Text [PDF 791 kb]   (714 Downloads) |   |   Full-Text (HTML)  (1737 Views)  
Type of Study: case report | Subject: Special
Received: 2018/02/25 | Accepted: 2018/07/27 | Published: 2018/10/1

1. ATLANTIS Trial coordinators. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004; 363(9411):768-74. [DOI:10.1016/S0140-6736(04)15692-4] [DOI:10.1016/S0140-6736(04)15692-4]
2. Hill MD, Kenney C, Dzialowski I, Boulanger JM, Demchuk AM, Barber PA, et al. Tissue Window in Stroke Thrombolysis study (TWIST): A safety study. Can J Neurol Sci. 2013; 40(01):17-20. [DOI:10.1017/S0317167100012890] [DOI:10.1017/S0317167100012890]
3. Mishra NK, Lyden P, Grotta JC, Lees KR. Thrombolysis is associated with consistent functional improvement across baseline stroke severity a comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke. 2010; 41(11):2612-7. [DOI:10.1161/STROKEAHA.110.589317] [PMID] [DOI:10.1161/STROKEAHA.110.589317]
4. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013; 309(23):2480-8. [DOI:10.1001/jama.2013.6959] [PMID] [DOI:10.1001/jama.2013.6959]
5. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, Von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274(13):1017-25. [DOI:10.1001/jama.1995.03530130023023] [DOI:10.1001/jama.1995.03530130023023]
6. Lees KR, Bluhmki E, Von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. The Lancet. 2010; 375(9727):1695-703. [DOI:10.1016/S0140-6736(10)60491-6] [DOI:10.1016/S0140-6736(10)60491-6]
7. Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, et al. Implementation and outcome of thrombolysis with alteplase 3–4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol. 2010; 9(9):866-74. [DOI:10.1016/S1474-4422(10)70165-4] [DOI:10.1016/S1474-4422(10)70165-4]
8. Bluhmki E, Chamorro Á, Dávalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0–4.5 h after onset of acute ischaemic stroke (ECASS III): Additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009; 8(12):1095-102. [DOI:10.1016/S1474-4422(09)70264-9] [DOI:10.1016/S1474-4422(09)70264-9]
9. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13):1317-29. [DOI:10.1056/NEJMoa0804656] [PMID] [DOI:10.1056/NEJMoa0804656]
10. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998; 352(9136):1245-51. [DOI:10.1016/S0140-6736(98)08020-9] [DOI:10.1016/S0140-6736(98)08020-9]
11. Ogata T, Christensen S, Nagakane Y, Ma H, Campbell BC, Churilov L, et al. The effects of alteplase 3 to 6 hours after stroke in the EPITHET–DEFUSE combined dataset post hoc case–control study. Stroke. 2013; 44(1):87-93. [DOI:10.1161/STROKEAHA.112.668301] [PMID] [DOI:10.1161/STROKEAHA.112.668301]
12. Arenillas J, Ispierto L, Millan M, Escudero D, de la Ossa NP, Dorado L, et al. Metabolic syndrome and resistance to IV thrombolysis in middle cerebral artery ischemic stroke. Neurol. 2008; 71(3):190-5. [DOI:10.1212/01.wnl.0000317092.21210.e6] [PMID] [DOI:10.1212/01.wnl.0000317092.21210.e6]
13. Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke. Stroke. 2000; 31(8):1812-6. [DOI:10.1161/01.STR.31.8.1812] [DOI:10.1161/01.STR.31.8.1812]
14. Martins SCO, Friedrich MAG, Brondani R, de Almeida AG, de Araújo MDA, Chaves MLF, et al. Thrombolytic therapy for acute stroke in the elderly: an emergent condition in developing countries. J Stroke Cerebrovasc Dis. 2011; 20(5):459-64. [DOI:10.1016/j.jstrokecerebrovasdis.2010.02.019] [PMID] [DOI:10.1016/j.jstrokecerebrovasdis.2010.02.019]
15. Mishra NK, Ahmed N, Andersen G, Egido JA, Lindsberg PJ, Ringleb PA, et al. Thrombolysis in very elderly people: controlled comparison of SITS international stroke thrombolysis registry and virtual international stroke trials archive. BMJ. 2010; 341. [DOI:10.1136/bmj.c6046] [DOI:10.1136/bmj.c6046]
16. Paliwal PR, Ahmad A, Shen L, Yeo L, Loh PK, Ng K, et al. Persistence of hyperdense middle cerebral artery sign on follow-up CT scan after intravenous thrombolysis is associated with poor outcome. Cerebrovasc Dis. 2011; 33(5):446-52. [DOI:10.1159/000336863] [PMID] [DOI:10.1159/000336863]
17. Rubiera M, Ribo M, Delgado-Mederos R, Santamarina E, Delgado P, Montaner J, et al. Tandem internal carotid artery/middle cerebral artery occlusion an independent predictor of poor outcome after systemic thrombolysis. Stroke. 2006;37(9):2301-5. [DOI:10.1161/01.STR.0000237070.80133.1d] [PMID] [DOI:10.1161/01.STR.0000237070.80133.1d]
18. Muchada M, Rubiera M, Rodriguez-Luna D, Pagola J, Flores A, Kallas J, et al. Baseline national institutes of health stroke scale–adjusted time window for intravenous tissue-type plasminogen activator in acute ischemic stroke. Stroke. 2014; 45(4):1059-63. [DOI:10.1161/STROKEAHA.113.004307] [PMID] [DOI:10.1161/STROKEAHA.113.004307]
19. Gumbinger C, Reuter B, Stock C, Sauer T, Wiethölter H, Bruder I, et al. Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials. BMJ. 2014; 348. [DOI:10.1136/bmj.g3429] [DOI:10.1136/bmj.g3429]
20. Li BH, Ding X, Yin YW, Liu Y, Gao CY, Zhang LL, et al. Meta-analysis of clinical outcomes of intravenous recombinant tissue plasminogen activator for acute ischemic stroke: within 3 hours versus 3-4.5 hours. Curr Med Res Opin. 2013; 29(9):1105-14. [DOI:10.1185/03007995.2013.818533] [PMID] [DOI:10.1185/03007995.2013.818533]
21. O'Brien EC, Rose KM, Patel MD, Murphy CV, Rosamond WD. Clinical outcomes among stroke patients receiving tissue plasminogen activator therapy beyond the 3-hour time window. J Stroke Cerebrovasc Dis. 2012; 21(7):541-6. [DOI:10.1016/j.jstrokecerebrovasdis.2010.12.004] [PMID] [DOI:10.1016/j.jstrokecerebrovasdis.2010.12.004]
22. Ramaiah SS, Yan B. Low-dose tissue plasminogen activator and standard-dose tissue plasminogen activator in acute ischemic stroke in Asian populations: A review. Cerebrovasc Dis. 2012; 36(3):161-6. [DOI:10.1159/000354162] [PMID] [DOI:10.1159/000354162]
23. Friedman HS, Koroshetz W, Qureshi N. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1996; 334:1405. [DOI:10.1056/NEJM199605233342114] [PMID] [DOI:10.1056/NEJM199605233342114]
24. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick J, et al. ATLANTIS trials investigators; ECASS trials investigators; NINDS rt-PA study group investigators. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004; 363(9411):768-74. [DOI:10.1016/S0140-6736(04)15692-4] [DOI:10.1016/S0140-6736(04)15692-4]
25. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset Japan alteplase clinical trial (J-ACT). Stroke. 2006; 37(7):1810-5. [DOI:10.1161/01.STR.0000227191.01792.e3] [PMID] [DOI:10.1161/01.STR.0000227191.01792.e3]
26. Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al. Thrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice The Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke. 2010; 41(9):1984-9. [DOI:10.1161/STROKEAHA.110.589606] [PMID] [DOI:10.1161/STROKEAHA.110.589606]
27. Ghandehari K. Design of a standard Iranian protocol of Intravenous thrombolysis with tissue plasminogen activator: A national project. Iran J Neurol. 2013; 12(2):72-4. [PMID] [PMCID] [PMID] [PMCID]
28. Brott T, Haley E, Levy D, Barsan W, Broderick J, Sheppard G, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992; 23(5):632-40. [DOI:10.1161/01.STR.23.5.632] [DOI:10.1161/01.STR.23.5.632]
29. Haley E, Levy DE, Brott TG, Sheppard GL, Wong M, Kongable GL, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke. 1992; 23(5):641-5. [DOI:10.1161/01.STR.23.5.641] [DOI:10.1161/01.STR.23.5.641]
30. Khatri P, Broderick JP, Pancioli AM. Risk of thrombolysis-associated intracerebral hemorrhage: the need to compare apples with apples. Stroke. 2005; 36(6):1109-10. [DOI:10.1161/01.STR.0000166008.72738.fd] [DOI:10.1161/01.STR.0000166008.72738.fd]
31. Aleu A, Mellado P, Lichy C, Köhrmann M, Schellinger PD. Hemorrhagic complications after off-label thrombolysis for ischemic stroke. Stroke. 2007; 38(2):417-22. [DOI:10.1161/01.STR.0000254504.71955.05] [PMID] [DOI:10.1161/01.STR.0000254504.71955.05]
32. De Silva D, Manzano J, Chang H, Wong M. Reconsidering recent myocardial infarction as a contraindication for IV stroke thrombolysis. Neurology. 2011; 76(21):1838-40. [DOI:10.1212/WNL.0b013e31821ccc72] [PMID] [DOI:10.1212/WNL.0b013e31821ccc72]
33. Guillan M, Alonso-Canovas A, Garcia-Caldentey J, Sanchez-Gonzalez V, Hernandez-Medrano I, DeFelipe-Mimbrera A, et al. Off-label intravenous thrombolysis in acute stroke. Eur J Neurol. 2012; 19(3):390-4. [DOI:10.1111/j.1468-1331.2011.03517.x] [PMID] [DOI:10.1111/j.1468-1331.2011.03517.x]
34. Huttner LBCBH, Köhrmann IKSSM. Off-label thrombolysis for acute ischemic stroke: Rate, clinical outcome and safety are influenced by the definition of 'minor stroke'. Cerebrovasc Dis. 2011; 32:177-85. [DOI:10.1159/000328811] [PMID] [DOI:10.1159/000328811]
35. Rubiera M, Ribo M, Santamarina E, Maisterra O, Delgado-Mederos R, Delgado P, et al. Is it time to reassess the SITS-MOST criteria for thrombolysis? A comparison of patients with and without SITS-MOST exclusion criteria. Stroke. 2009; 40(7):2568-71. [DOI:10.1161/STROKEAHA.108.538587] [PMID] [DOI:10.1161/STROKEAHA.108.538587]
36. Jauch EC, Saver JL, Adams HP, Bruno A, Demaerschalk BM, Khatri P, et al. Guidelines for the early management of patients with acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(3):870-947. [DOI:10.1161/STR.0b013e318284056a] [PMID] [DOI:10.1161/STR.0b013e318284056a]
37. Seet R, Rabinstein AA. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Cerebrovasc Dis. 2011; 34(2):106-14. [DOI:10.1159/000339675] [PMID] [DOI:10.1159/000339675]
38. González RG, Furie KL, Goldmacher GV, Smith WS, Kamalian S, Payabvash S, et al. Good outcome rate of 35% in IV-tPA–treated patients with computed tomography angiography confirmed severe anterior circulation occlusive stroke. Stroke. 2013; 44(11):3109-13. [DOI:10.1161/STROKEAHA.113.001938] [PMID] [PMCID] [DOI:10.1161/STROKEAHA.113.001938]
39. Lyerly MJ, Albright KC, Boehme AK, Shahripour RB, Houston JT, Rawal PV, et al. Safety of protocol violations in acute stroke tPA administration. J Stroke Cerebrovasc Dis. 2014; 23(5):855-60. [DOI:10.1016/j.jstrokecerebrovasdis.2013.07.019] [PMID] [PMCID] [DOI:10.1016/j.jstrokecerebrovasdis.2013.07.019]
40. De Keyser J, Gdovinová Z, Uyttenboogaart M, Vroomen PC, Luijckx GJ. Intravenous alteplase for stroke beyond the guidelines and in particular clinical situations. Stroke. 2007; 38(9):2612-8. [DOI:10.1161/STROKEAHA.106.480566] [PMID] [DOI:10.1161/STROKEAHA.106.480566]
41. Ghandehari K. Barriers of thrombolysis therapy in developing countries. Stroke Res Treat. 2011; 686797. [DOI:10.4061/2011/686797] [DOI:10.4061/2011/686797]
42. Ghandehari K, Foroughipour M, pourzahedA, Taheri M, Abbasi M, Gorjestani S. Thrombolysis in stroke patients: Problems and limitations. Iran J Med Sci. 2010; 35(2):17-9.
43. Ghandehari K, pourzahedA, Taheri M, Abbasi M, Gorjestani S, Moghaddam Ahmadi A. Estimation of Iranian stroke patients eligible for intravenous thrombolysis with tPA. Int J Stroke. 2009; 4(4):1747-8. [DOI:10.1111/j.1747-4949.2009.00273.x] [DOI:10.1111/j.1747-4949.2009.00273.x]
44. Menon BK, Saver JL, Prabhakaran S, Reeves M, Liang L, Olson DM, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke. 2012; 43(9):2293-9. [DOI:10.1161/STROKEAHA.112.660415] [PMID] [DOI:10.1161/STROKEAHA.112.660415]
45. Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator a systematic review and meta-analysis of 55 studies. Stroke. 2012; 43(11):2904-9. [DOI:10.1161/STROKEAHA.112.665331] [PMID] [DOI:10.1161/STROKEAHA.112.665331]
46. Al-Khaled M, Matthis C, Eggers J. Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.J Stroke Cerebrovasc Dis. 2014; 23(1):7-11. [DOI:10.1016/j.jstrokecerebrovasdis.2012.04.004] [PMID] [DOI:10.1016/j.jstrokecerebrovasdis.2012.04.004]
47. Whiteley WN, Thompson D, Murray G, Cohen G, Lindley RI, Wardlaw J, et al. Targeting Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Based on Risk of Intracranial Hemorrhage or Poor Functional Outcome An Analysis of the Third International Stroke Trial. Stroke. 2014; 45(4):1000-6. [DOI:10.1161/STROKEAHA.113.004362] [PMID] [PMCID] [DOI:10.1161/STROKEAHA.113.004362]
48. McKinney JS, Cucchiara B. Risk scores for predicting post-thrombolysis intracerebral hemorrhage. US Neurol. 2010; 5(2):39-40. [DOI:10.17925/USN.2010.05.02.39] [DOI:10.17925/USN.2010.05.02.39]
49. Daniel S, Patrik M, David S, Jeffery S, Heikki N, Atte M, et al. Symptomatic Intracranial hemorrhage after stroke thrombolysis: Comparison of prediction scores. Stroke. 2014; 45:752-8. [DOI:10.1161/STROKEAHA.113.003806] [PMID] [DOI:10.1161/STROKEAHA.113.003806]
50. Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuck AM, Fugate JE, Grotta JC, et al. Scientific rational for the inclusion and exclusion criteria for intravenous Alteplase in acute ischemic stroke. Stroke. 2016; 2015; 47:581-641. [DOI:10.1161/STR.0000000000000086] [PMID] [DOI:10.1161/STR.0000000000000086]

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.